Skip to main content
. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094

Figure 1.

Figure 1

Antitumor activity of ENMD-2076 in p53-mutated triple-negative breast cancer (TNBC) PDX models in vivo. (A) Effect of ENMD-2076 treatment (200 mg/kg once daily by oral gavage) in three PDX models. Tumor growth inhibition (TGI) in vivo was statistically significant in CU_TNBC_002 and CU_TNBC_005 (TGI 71.3%, ****p < 0.0001; TGI 66.1%, ***p < 0.001, respectively). Treatment with ENMD-2076 did not result in a statistically significant decrease in TGI in the CU_TNBC_004 model (TGI 37.0%, p > 0.05). The baseline molecular analysis is provided for each model, including p53 mutation and TNBC subtype using TNBCtype (20). (B) Immunofluorescence analysis of phospho-AurA (pAurA), phospho-histone H3, and DAPI control in CU_TNBC_005 and CU_004 tumors harvested from mice treated with ENMD-2076 or vehicle at the time points noted. Representative images were acquired using confocal microscopy at 60× magnification. Scale = 5 µm.